Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2

Conditions

Breast Neoplasms 37Carcinoma, Non-Small-Cell Lung 28Glioblastoma 24Brain Neoplasms 23Esophageal Neoplasms 20Rectal Neoplasms 19Stomach Neoplasms 17Glioma 17Lung Neoplasms 16Colorectal Neoplasms 16Astrocytoma 14Pancreatic Neoplasms 12Central Nervous System Neoplasms 12Squamous Cell Carcinoma of Head and Neck 10Neoplasm Metastasis 10Head and Neck Neoplasms 10Gliosarcoma 10Sarcoma 9Oligodendroglioma 9Recurrence 8Neoplasms 8Adenocarcinoma Of Esophagus 8Esophageal Squamous Cell Carcinoma 7Uterine Cervical Neoplasms 6Ovarian Neoplasms 6Colonic Neoplasms 6Pilonidal Sinus 5Melanoma 5Carcinoma, Ovarian Epithelial 5Adenocarcinoma of Lung 5

Interventions

pembrolizumab 124Cisplatin 27lenvatinib 24Carboplatin 24Paclitaxel 19Docetaxel 16Fluorouracil 13Capecitabine 11Pemetrexed 10Gemcitabine 10Saline Solution 8Oxaliplatin 8epacadostat 6Leucovorin 5Irinotecan 5Cetuximab 5olaparib 4Bevacizumab 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4trifluridine tipiracil drug combination 3regorafenib 3enzalutamide 3durvalumab 3Nivolumab 3Etoposide 3trametinib 2etoposide phosphate 2dabrafenib 2Tretinoin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Parkinson Disease 4, Autosomal Dominant Lewy Body × Surgical Procedures, Operative × Clear all
NCT03924856 2026-05-28

KEYNOTE-866

Merck Sharp & Dohme LLC

Phase 3 Completed
907 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT04700124 2026-02-05

KEYNOTE-B15

Merck Sharp & Dohme LLC

Phase 3 Completed
808 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡